Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Lineage Cell Therapeutics, Inc. (LCTX)

1.18   0 (0%) 09-24 15:47
Open: 1.17 Pre. Close: 1.18
High: 1.18 Low: 1.11
Volume: 434,398 Market Cap: 200(M)
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.18 - 1.19 1.19 - 1.2
Low: 1.09 - 1.1 1.1 - 1.11
Close: 1.16 - 1.18 1.18 - 1.19

Technical analysis

as of: 2022-09-23 4:25:33 PM
Overall:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 1.59     One year: 1.77
Support: Support1: 1.11    Support2: 0.92
Resistance: Resistance1: 1.36    Resistance2: 1.51
Pivot: 1.27
Moving Average: MA(5): 1.19     MA(20): 1.31
MA(100): 1.42     MA(250): 1.67
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 10.3     %D(3): 8.6
RSI: RSI(14): 26.3
52-week: High: 2.71  Low: 1.1
Average Vol(K): 3-Month: 385 (K)  10-Days: 342 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ LCTX ] has closed above bottom band by 11.1%. Bollinger Bands are 9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Mon, 19 Sep 2022
The Three Best Anti-Aging Stocks to Buy in September - InvestorPlace

Mon, 15 Aug 2022
Lineage to Present at H.C. Wainwright & Co. 2nd Annual Virtual Ophthalmology Conference - Business Wire

Fri, 12 Aug 2022
Lineage Cell Therapeutics, Inc. (LCTX) Q2 2022 Earnings Call Transcript - The Motley Fool

Thu, 04 Aug 2022
Lineage Cell Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 11, 2022 - Yahoo Finance

Mon, 01 Aug 2022
Premarket Mover: Lineage Cell Therapeutics Inc (LCTX) Up 3.05% - InvestorsObserver

Thu, 05 May 2022
Lineage Cell Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 12, 2022 - Business Wire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  AMEX
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 169 (M)
Shares Float 127 (M)
% Held by Insiders 4.4 (%)
% Held by Institutions 45.5 (%)
Shares Short 10,350 (K)
Shares Short P.Month 7,660 (K)

Stock Financials

EPS -0.08
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.72
Profit Margin (%) 0
Operating Margin (%) -741.4
Return on Assets (ttm) -14
Return on Equity (ttm) -11.5
Qtrly Rev. Growth 297.5
Gross Profit (p.s.) 0
Sales Per Share 0.02
EBITDA (p.s.) -0.15
Qtrly Earnings Growth 0
Operating Cash Flow -23 (M)
Levered Free Cash Flow -13 (M)

Stock Valuations

PE Ratio -14.75
PEG Ratio 0
Price to Book value 1.63
Price to Sales 56.34
Price to Cash Flow -8.53

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.